By Sabela Ojea

Bayer said Friday the Food and Drug Administration has approved its Ultravist injection to visualize breast lesions as an adjunct to mammographies or ultrasounds.

The pharmaceutical company said Ultravist-300 and -370 gives physicians a new imaging option beyond conventional mammographies.

"The new FDA-approved indication aligns with the recent increased focus on supplemental imaging needs for women at a higher risk for breast cancer," Bayer said.

Ultravist is an injection for intravenous and intra-arterial use.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

June 23, 2023 14:21 ET (18:21 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Bayer Aktiengesellschaft (PK).
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Bayer Aktiengesellschaft (PK).